Despite the abundance of information on cutaneous malignancies associated with solid organ transplantation in the transplant literature, there is limited information regarding nonmalignant skin changes after transplantation. There are numerous skin toxicities secondary to immunosuppressive and other transplant-related medications that can vary in presentation, severity, and prognosis. To limit associated morbidity and mortality, solid organ transplant recipient care providers should effectively identify and manage cutaneous manifestations secondary to drug toxicity. Toxicities from the following transplantrelated medications will be discussed: antithymocyte globulins, systemic steroids, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mammalian target of rapamycin inhibitors sirolimus and everolimus, basiliximab and daclizumab, belatacept, and voriconazole.
Introduction
Although cutaneous malignancies associated with solid organ transplantation are well described in the transplant literature, there is limited information regarding nonmalignant skin changes after transplantation. Drug toxicity, infection, and malignancy can all be sources of skin pathology in solid organ transplant recipients (SOTRs). We discuss the numerous skin toxicities secondary to immunosuppressive and other transplantation-related medications that may cause significant morbidity to SOTRs. It is beneficial for transplant care providers to recognize the spectrum and management of cutaneous toxicities secondary to transplantation-related medications.
Antithymocyte globulins
Beore transplantation and during rejection episodes, many recipients undergo induction with antithymocyte globulins (ATG), which, in being generated in rabbits or horses, can induce serum sickness, an immune complex-mediated hypersensitivity disease. Serum sickness is common and occurs in 7-27% of renal transplant recipients who receive ATG (1) . The reaction onset is 7-14 days after initial exposure to ATG but only 12-36 h in patients reexposed to ATG. Serum sickness presents with an urticarial morbilliform rash, temperature of >101°F, polyarthralgia or frank arthritis, small vessel vasculitis, and lymphadenopathy. The urticarial plaques are the earliest manifestation of serum sickness and last for days to weeks. The rash starts on the abdomen, groin, or axillae before spreading to the rest of the trunk and extremities. Characteristic of serum sickness, the rash may be prominent at the lateral aspect of acral surfaces, at the junction of the sole and side of the foot, or at the border between the palm and dorsal skin. The diagnosis of serum sickness is made on clinical grounds; skin biopsies are not necessary in most cases. Along with these skin changes, a reduction in glomerular filtration rate and urine analysis may reveal a mild proteinuria and hematuria without casts, but the dysfunction is transient. Treatment consists of discontinuing ATG and starting oral prednisone 0.5-1 mg/kg daily tapered rapidly over 1 week (2) . If severe symptoms persist despite administration systemic steroids for 3 days, therapeutic plasma exchange should be initiated.
Systemic steroids
Systemic corticosteroids are used in many immunosuppressive regimens, often prescribed at higher doses early in the posttransplantation period before being tapered to low doses or discontinued. Cutaneous complications of systemic steroids include steroid acne, skin fragility, purpura, striae, altered wound healing, and exogenous Cushing syndrome (Figure 1 ). Skin changes were observed in nearly half of the patients treated with prednisone doses of >20 mg/day for 3 months (3). Steroid acne is characterized by abrupt onset of monomorphic erythematous papules and pustules on the upper trunk. Compared with acne vulgaris, steroid acne rarely presents with comedones, cysts, nodules, and scarring. Treatment includes topical retinoids such as adapalene 0.1% or tazarotene 0.1%. Additionally, benzoyl peroxide 2.5% with topical antibiotics including erythromycin 2% or clindamycin 1% or oral doxycycline 100 mg daily may resolve lesions. When these methods are not efficacious, then the steroid dose may need to be reduced.
Skin fragility and purpura occur with weeks to months of commencing systemic steroids. Steroids can reduce the collagen synthesis, decrease fibroblast proliferation, and downregulate elastin synthesis, the cumulative effect is manifested by easy tearing and bruising of the skin. Mild atrophy is reversible by reducing or stopping the steroids; once significant atrophy has developed, the changes may be permanent. Topical tazarotene 0.1% gel and ammonium lactate may minimize atrophy and related purpura (4) . By inhibiting fibroblast function and collagen production along with inhibiting angiogenesis and the production of ground substance, systemic steroids may also limit reepithelialization of wounds (5) . Topical retinoids may be helpful in promoting wound healing in patients taking systemic steroids.
Striae distensae secondary to systemic steroids appear on the abdomen, thighs, and buttocks ( Figure 1A) . A primarily cosmetic concern, striae are difficult to treat. The use of topical agents and laser treatments may improve the appearance of striae, but no current therapeutic option is effective while having minimal adverse effects (6, 7) . The development of cushingoid features, defined as redistribution of body fat with truncal obesity, buffalo hump, and moon face ( Figure 1B) , is dependent on both steroid dose and duration. These features were found in 25% of patients who had received >7.5 mg of prednisone daily for 1 year compared with only 4% of those taking <5 mg daily (8) . Reduction in or elimination of the steroid may resolve the cushingoid features.
Cyclosporine
Most of the cutaneous changes due to cyclosporine therapy involve the pilosebaceous unit: hypertrichosis, sebaceous hyperplasia, acne, folliculitis, epidermal cysts, and pilar keratosis (9) (Figure 2 ). Sebaceous hyperplasia, a benign proliferation of the sebaceous gland presenting as multiple yellow umbilicated papules on the forehead and other parts of the face, occurs in up to 30% of transplant recipients taking cyclosporine (10) ( Figure 2B ). Treatment consists of destructive methods, including cryotherapy, superficial chemical peels, laser treatment, excision, and electrodessication. Systemic isotretinoin 1 mg/kg daily may also help clear sebaceous hyperplasia (11, 12) .
Hypertrichosis affects up to 70% of patients taking cyclosporine, and its incidence is dose dependent (10) ( Figure 2D ). Cyclosporine releases the inhibition of a nuclear factor on hair follicle stem cells, and this subsequently increases the anagen phase of hair growth on the face and body (13) . Given the effects of unwanted hair on self-image and self-esteem, laser hair removal may be pursued. In those who do not see an effect of laser hair removal, switching from cyclosporine to tacrolimus typically resolves hypertrichosis (14) .
Gingival overgrowth is a well-known side effect of cyclosporine, occurring in one-third of patients after 3 months of therapy. The gingival overgrowth induced by cyclosporine is similar to that caused by phenytoin, with growth beginning in the anterior labial interproximal gingiva ( Figure 2C ). The pathogenesis of drug-induced gingival overgrowth is not well understood, but there is some evidence that dental plaque and gingivitis may predispose to gingival hyperplasia (15) . Poor oral hygiene leads to inflammation that may promote a decrease in the matrix metalloproteinases (16) . Improved oral hygiene and reduction of cyclosporine dose may be the first steps to reduce gingival overgrowth. Azithromycin 500 mg daily for 3 days in conjunction with improved oral hygiene may help reverse the overgrowth (17, 18) .
Acne due to cyclosporine is typically nodulocystic compared with the papular acne induced by steroids. Systemic antibiotics and oral isotretinoin are the most effective treatments for this type of acne. If a patient taking cyclosporine is to receive isotretinoin, it is important to closely monitor serum lipid levels (19) . Cyclosporine may also cause pseudofolliculitis barbae, a chronic, inflammatory disorder that commonly affects facial hair-bearing areas with folliculocentric papules, pustules, and postinflammatory hyperpigmentation. Drug-induced pseudofolliculitis barbae is resistant to conservative treatment measures and may require cyclosporine dose reduction (20) .
Tacrolimus
Compared with cyclosporine, tacrolimus has a limited cutaneous side effect profile. In one study, 29% of patients taking tacrolimus developed a telogen effluvium, a nonscarring, diffuse alopecia (21) . Telogen effluvium involves a large proportion of hair follicles prematurely shifting into the telogen phase, leading to widespread thinning and shedding of hair ( Figure 2A ) (22) . Telogen effluvium may develop an average of 1-14 months after the initiation of tacrolimus. The hair loss resolves once tacrolimus is discontinued. It is postulated that this hair loss is secondary to tacrolimus-induced vasoconstriction. If discontinuing tacrolimus is not an option, topical minoxidil 5% foam 1 mL twice daily may be effective in treating tacrolimus-induced alopecia (21, 23) .
Azathioprine
Cutaneous side effects of azathioprine (AZA) are typically due to type IV hypersensitivity reactions, with up to 2% of patients affected (24) . The onset of AZA hypersensitivity reaction is 1-4 weeks after initiation of the medication.
Patients present with fever, arthralgia, myalgia, nausea, vomiting, and rash (25) . Patients with underlying inflammatory bowel disease are prone to cutaneous manifestations associated with a hypersensitivity response (26) . Cutaneous manifestations of AZA hypersensitivity include macules, papules, vesicles, pustules, erythema nodosum, urticaria, and plaques mimicking neutrophilic dermatoses (e.g. Sweet syndrome) (27) (28) (29) (30) (31) (32) (33) (34) . AZA-induced plaques are nontender and lack histologic features suggestive of Sweet syndrome (25) . Additional cutaneous side effects of AZA include mild alopecia and increased photosensitivity (35) . AZA hypersensitivity is managed with discontinuation of the drug.
Mycophenolate mofetil Similar to tacrolimus, mycophenolate mofetil (MMF) has limited cutaneous toxicities. Aphthous stomatitis is a common side effect that presents as discrete oral ulcers with a grayish pseudo-membrane on the buccal mucosa and ventral tongue (36) . Although 25% of individuals within the nonimmunosuppressed population develop aphthous ulcers, patients taking MMF often have more severe cases with larger or clustered ulcerations. Aphthous ulcers histologically show infiltration with neutrophils and histiocytes along with perivascular inflammatory infiltrate (37) . The severity of aphthae is worsened in patients taking mammalian target of rapamycin(mTOR) inhibitors along with MMF (38) . Acne, peripheral edema, and worsening of dyshidrotic eczema develop in 10% of transplant recipients (39) . The use of systemic and topical isotretinoin for 6 months to manage acne has been successful (40) . Aphthous ulcers have been observed to regress within 7-10 days after discontinuation of MMF (41-45).
mTOR inhibitors: sirolimus and everolimus Sirolimus and everolimus may cause multiple cutaneous toxicities, including aphthous ulcers, impaired wound healing, and pilosebaceous dermatoses, such as inflammatory papules, pustules, or painful nodules ( Figure 3 ) (46, 47) . Sirolimus therapy is also associated with leukocytoclastic vasculitis, onycholysis, erythema, splinter hemorrhages, and pyogenic granulomas (48) .
Aphthous ulcers occur in 10-20% of SOTRs taking sirolimus. These ulcers can present as small, discrete lesions or as larger lesions (>1 cm), which are referred to as aphthous stomatitis of the major type (36) . The incidence of sirolimus-induced aphthous stomatitis is dose dependent; therefore, it is important to ensure that serum levels are not supratherapeutic (49, 50) . Aphthous ulcers can cause severe pain and anorexia and may recur (51) . Although sirolimus dose reduction or cessation can lead to ulcer resolution, potent topical steroid therapy with clobetasol 0.05% cream provides rapid resolution of lesions (51, 52) . Diagnosis is made clinically, and biopsy should be reserved for ulcers that persist for several weeks. It is important to consider cytomegalovirus (CMV) infection in transplant recipients who present with chronic ulcers. One study found that 50% of oral aphthous-like ulcers in renal transplant patients had evidence of CMV infection (53) . Aphthous ulcer etiology can be challenging to determine because the presentation in SOTRs is similar regardless of the cause (54) . It is recommended that SOTRs with chronic oral aphthous-like ulcers are trialed with intravenous ganciclovir 5 mg/kg, as this leads to rapid resolution of CMV-induced lesions.
Palmoplantar peeling has been associated with the initiation of sirolimus ( Figure 3A ). This palmoplantar peeling leads to discomfort on use of hands and feet. This condition can resolve on discontinuation of sirolimus and may also resolve spontaneously (55) .
Transplant recipients taking mTOR inhibitors have a higher rate of wound-healing complications compared with patients taking alternative immunosuppressive regimens (56) (57) (58) . A study involving 158 renal transplant recipients found that the incidence of wound-related issues was 43.2% for the sirolimus group versus 2.4% for the MMF group (56). These wound-healing complications include superficial or fascial wound dehiscence, infection, and fluid collections, such as seromas or hematomas. Further, chronic ulcers of the lower extremities have been associated with sirolimus and resolve on discontinuation of the mTOR inhibitor (59) . Sirolimus is believed to inhibit the activity of various growth factors involved in wound repair, particularly mTOR-mediated vascular endothelial growth factor (VEGF) activity, an essential component of wound healing (60) (61) (62) . A study that followed renal transplant recipients who were taking sirolimus found that of 45 wound-healing complications, 9% were due to cellulitis (57) .
The majority of wound-healing complications due to sirolimus can be managed with outpatient standard clinical practice. Wound dehiscence can be managed with surgical debridement and, often, subsequent secondary intention healing. Skin site infection requires appropriate antibiotic treatment. Pockets of lymphatic fluid, such as perigraft fluid collections, may require drainage. Sirolimus therapy is not discontinued in patients with minor wound-healing complications. To help reduce would healing issues in the future, cessation or early withdrawal of corticosteroids is recommended (57).
Around 1 month after initiation of sirolimus, 15-45% of patients (75% of whom are men) develop an acneiform eruption (46) , which presents as erythematous papules and pustules on the head more than the trunk (Figure 3B ) (47) . Other presentations of pilosebaceous inflammation in SOTRs include folliculitis, hidradenitis suppurativa, furuncles, and chalazion. The pathogenesis of this side effect is attributed to inhibition of epidermal growth factor signaling due to mTOR inhibition. Diagnosis is made clinically, and treatment involves standard acne care, including benzoyl peroxide 2.5% with topical erythromycin 2% or clindamycin 1%, topical and systemic isotretinoin, and oral doxycycline 100 mg or minocycline 50 mg daily.
Peripheral edema is a relatively common side effect of sirolimus in SOTRs, but there is no relationship to dosage, time from starting sirolimus, time since transplantation, patient age, or medical history (63) . In a study of 175 liver transplant recipients taking sirolimus and a corticosteroid, 35% of patients developed some type of edema, predominantly of the leg (57%) (63) . The development of peripheral edema is considered multifactorial but is linked to the reduced production of VEGF, which is thought to affect vascular permeability along with lymphangiogenesis (62, 64) . A rare complication in transplant recipients taking sirolimus therapy is the development of lymphedema ( Figure 3D ). Lymphedema is likely due to impairment of lymphatic drainage because of sirolimusinduced effects on lymphangiogenesis related to mTOR inhibition (65) . If left untreated, chronic edema may lead to lymphedema or stasis dermatitis. Stasis dermatitis is a vascular disease owing to venous insufficiency and venous hypertension. It presents as erythematous, scaly plaques with purple mottling and patches of brown pigmentation, most commonly on the distal lower extremity. Peripheral edema is associated with chronic venous ulcer formation, which explains the higher rates of lower extremity ulcers in sirolimus-treated patients. These present as irregularly shaped ulcers of varying depths with an overlying yellow exudate covering the wound bed ( Figure 3C ) (66) . Management of sirolimus-induced edema involves conservative measures such as dietary salt restriction, extremity elevation, and compression therapy. With resistant cases, discontinuation of sirolimus may be necessary.
mAbs Basiliximab and daclizumab are interleukin-2 receptordirected mAbs that are used to prevent acute rejection in SOTRs (67, 68) . Although cases of severe acute hypersensitivity reactions have been reported with both drugs, they have a side-effect profile similar to that of placebo (69, 70) . Acute hypersensitivity reactions may present with urticaria and a rash, usually within 24 h of drug administration. Such a reaction warrants immediate cessation of the particular drug. In SOTRs treated with basiliximab, 3-10% reported development of either cysts, herpes simplex, herpes zoster, hypertrichosis, pruritus, rash, or ulceration (69).
Newer immunosuppressive agents
Belatacept is a B7 ligand antagonist with a limited side effect prolife that is an emerging biologic for maintenance immunosuppression in SOTRs (71) . A study (72) found that peripheral edema occurred in 35% of SOTRs treated with belatacept. Hirsutism has been reported in 1% of patients taking belatacept.
Voriconazole
Transplant recipients commonly receive prophylactic voriconazole for the prevention or treatment of fungal infections. Approximately 8% of transplant patients treated with voriconazole show cutaneous side effects, including increased photosensitivity, cheilitis, worsening of psoriasis, alopecia, and pruritus. The most common manifestation is the increased photosensitivity, which presents with isolated erythema, bullous erythema, pseudoporphyria, or erythema with cheilitis, lentigines, or keratoses (73) . There is a genetic polymorphism associated with decreased metabolism of voriconazole that may predispose certain patients to photosensitivity (74) . An alternate antifungal should be considered in place of voriconazole in transplant recipients with a high risk of skin cancer due to cases of phototoxicity leading to photocarcinogenesis. There are reports of patients with prolonged voriconazole therapy who developed increased photosensitivity that resolved on switching to posaconazole (75) (76) (77) (78) ; therefore, clinicians should consider posaconazole as an alternative. All transplant recipients treated with voriconazole should be informed about the potential phototoxic side effect and the importance of adequate photoprotection (79) (80) (81) (82) (83) .
Conclusion
SOTRs may present with a wide spectrum of cutaneous findings. Sources of skin pathology in transplant recipients include drug toxicity, infection, and malignancy. Skin toxicity associated with immunosuppressive agents and other transplantation-related medications can vary in presentation, severity, and prognosis. It is valuable for care providers of SOTRs to effectively identify and manage cutaneous manifestations secondary to drug toxicity to limit associated morbidity and mortality.
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